Xenobiotics in Chemical Carcinogenesis: Translational Aspects in Toxicology covers the translational toxicology of xenobiotics substances in carcinogenesis by explaining the toxicokinetic and toxicodynamic, toxicogenomic, biotransformation, and resistance mechanisms in the human body. The book begins with a historical review and link to future prospects for chemical carcinogenesis. It discusses major environmental xenobiotics and their risks in inducing cancer, along with content on toxic xenobiotics and their routes of exposure in humans, the role of xenobiotic metabolism in carcinogenesis, and the toxicokinetic and toxicodynamic of xenobiotics in cancer development.
Lastly, the book explores current achievements such as using toxicogenomics for predicting the carcinogenicity of xenobiotic substances and the challenges posed by carcinogenic xenobiotic substances when examining preventive methods, diagnosis, and the development of anticancer drugs for specific toxicants.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. A historical review and future prospective of chemical carcinogenesis2. Role of xenobiotics metabolism in carcinogenesis
3. Recalcitrant of toxic xenobiotics and its routes of exposure to human
4. Major environmental xenobiotics risk for different cancers
5. Toxicokinetic and toxicodynamic of xenobiotics in cancer development
6. Mechanism of oxidative stress in carcinogenesis induced by xenobiotics
7. Genotoxic and non-genotoxic activities of cancer-inducing xenobiotics
8. Modulation of epigenome by xenobiotics in cancer
9. Carcinogenic effects of nanomaterials with emphasis on nanoplastics
10. Endocrine disruptor activity of xenobiotics in carcinogenesis
11. Environmental exposures (Bisphenol A and phatalates) as xenoestrogens enhance risk for breast cancer
12. Biotransformation of toxic xenobiotics by human gut microbiota
13. Mechanism of resistance to toxic xenobiotics in human
14. Profiling the reactive metabolites of xenobiotics in cancer
15. Toxicogenomic for prediction of carcinogenicity of xenobiotic substances
Authors
Akhileshwar Kumar Srivastava CSIR-Central Food Technological Research Institute, Mysore, India. Dr. Akhileshwar Kumar Srivastava works as a Research Associate (ICMR) in CSIR-Central Food Technological Research Institute, Mysore, India. In his eight years of research, he has published approximately 20 research articles and book chapters in international and national journals of repute. His research specialization is primarily in the area of pharmacognosy with genetics, metabolomics, bioinformatics, and molecular biology-associated targeting cancer diseases. In addition, he has studied at Augusta University (formerly, Georgia Regents University) in Augusta, GA, United States on a J-1 Exchange Scholar Visa and at Ben-Gurion University, Israel. He is also a life member fellow in Indian Science Congress and Agriculture, Nutrition and Health Academy, United Kingdom. Dhruv Kumar Senior Associate Professor at School of Health Sciences and Technology, UPES University, Dehradun, India. Dr. Dhruv Kumar is a Senior Associate Professor at School of Health Sciences and Technology, UPES University, Dehradun, India and his current research is focused on autophagy, cancer cell metabolism, tumour microenvironment, exosomes, mutational heterogeneity, cancer prevention, drug designing, NGS and COVID-19. After completion of B.Sc. in Chemistry from Banaras Hindu University (BHU) and M.Sc. in Bioinformatics from University of Allahabad, India, he has completed his Ph.D. in Cellular, Molecular and Industrial Biology from the University of Bologna (UNIBO), under highly prestigious fellowship, Indo-Italian Government fellowship. After his Ph.D., he obtained Postdoctoral training at the University of Kansas Medical Center, USA. During his Postdoctoral training, he worked towards understanding the molecular mechanism(s) of autophagy regulation and apoptosis in cancer stem cells (prostate, pancreatic and breast), focusing on the metabolic cross-talk between the tumour microenvironment (cancer associated fibroblast (CAF)) and head and neck squamous cell carcinoma (HNSCC) via HGF/c-MET and bFGF/FGFR signalling pathways. He has also worked on structure based drug designing for several cancers, COVID-19, mutational heterogeneity in cancer. Currently, his lab is focusing on metabolic heterogeneity in solid tumours and structure based drug designing for cancer and COVID-19. He has published more than 100 research articles, reviews and book chapters in reputed journals. Divya Singh Scientist, Central Sericultural Research and Training Institute, Mysore, India. Dr. Divya Singh is presently working as a scientist in Central Sericultural Research and Training Institute, Mysore, India. Her research specialization is primarily in genetics, proteomics, metabolomics, toxicology, bioinformatics, and molecular biological evaluation in various in vivo and in vitro plant models to elucidate the physiological changes and evaluate the DNA damage potency. She has published morethan 10 research articles including book chapters. In addition, she is also a life member fellow of Indian Science Congress. Rajesh Kumar Singh Research Associate, Centre of Experimental Medicine and Surgery at Banaras Hindu University, India. Dr. Rajesh Kumar Singh is currently working as a Research Associate in Banaras Hindu University. His research focus is pharmacognosy, reverse pharmacology, drug design and discovery, extraction & isolation of natural products, cell culture, and handling of different rodents. He has published several research articles in reputable journals over the course of his career. At present, he is involved in developing an Indian origin cell line and screening drugs of natural origin for the treatment of gallbladder cancer.
